Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CASP2 | P42575 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.45 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30180923 | 0.86 | EPHX2 (0.50) | SMN1; SMN2CASP2FAAHTSHRDNM1 | |
| SCHEMBL12417323 | 0.85 | FAAH (0.57) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL23452883 | 0.85 | SMN1; SMN2 (0.45) | KDM4EMAPK1HIF1ASMN1; SMN2FAAH | |
| SCHEMBL14438828 | 0.85 | FAAH (0.61) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL14438832 | 0.85 | FAAH (0.61) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL14438830 | 0.85 | FAAH (0.61) | CASP2FAAHNAAADNM1EPHX2 | |
| SCHEMBL25517216 | 0.85 | SMN1; SMN2 (0.49) | KDM4EMAPK1HIF1AADRA1ASMN1; SMN2 | |
| SCHEMBL29324942 | 0.84 | SMN1; SMN2 (0.47) | SMN1; SMN2CASP2FAAHTSHRDNM1 | |
| SCHEMBL12734898 | 0.83 | EPHX2 (0.53) | KDM4EADRA1ASMN1; SMN2FAAHTSHR | |
| SCHEMBL13165219 | 0.83 | EPHX2 (0.53) | KDM4EADRA1ASMN1; SMN2FAAHTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10905665-B2 | Chemical modulators of signaling pathways and therapeutic use | DUKE UNIVERSITY (US) | 2021-02-02 | — | — | US | disclosed |
| US-20200038350-A1 | CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE | DUKE UNIVERSITY | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200038350-A1 | CHEMICAL MODULATORS OF SIGNALING PATHWAYS AND THERAPEUTIC USE | SFRP1, FZD7, WNT1 | KDM4E 2637/4885MAPK1 732/4885HIF1A 1710/4885 |
| US-10905665-B2 | Chemical modulators of signaling pathways and therapeutic use | SFRP1, FZD7, WNT1 | KDM4E 2637/4885MAPK1 732/4885HIF1A 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.